Japan’s Shimadzu Corporation collaborated with Drs William Redmond and Yoshinobu Koguchi of the Providence Cancer Institute…
Archive | Of Interest
Mass spec technology by Shimadzu unveils novel approach for immunotherapy success
Posted in Melanoma News, Health Professionals, Of Interest
U-M researchers target a protein channel in the cell’s lysosome to selectively kill cancer cells
Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal…
Posted in Melanoma News, Health Professionals, Of Interest
ImCheck publishes comprehensive overview of the development results of its first-in-class cancer immunotherapeutic targeting BTN3A to activate V?9V?2 T cells in Science Translational Medicine
Marseille, France, October 20, 2021 – ImCheck Therapeutics announced today the publication of the preclinical…
Posted in Melanoma News, Health Professionals, Of Interest
Discovery could help develop a new treatment strategy for patients with melanoma
A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity.
Posted in Melanoma News, Health Professionals, Of Interest
 |
 |
 |
 |
